Last updated on RxList: 6/15/2020
Cycloset Side Effects Center

What Is Cycloset?

Cycloset (bromocriptine mesylate) is a dopamine receptor agonist used together with diet and exercise to treat type 2 (non-insulin dependent) diabetes. Cycloset is not for treating type 1 diabetes.

What Are Side Effects of Cycloset?

Common side effects of Cycloset include:

  • dizziness,
  • spinning sensation,
  • drowsiness,
  • feeling weak or tired,
  • headache,
  • depression,
  • stuffy nose,
  • insomnia,
  • nausea,
  • vomiting,
  • upset stomach,
  • stomach pain,
  • loss of appetite,
  • diarrhea,
  • constipation, or
  • cold feeling or numbness in your fingers.

Tell your doctor if you have serious side effects of Cycloset including:

  • vision problems,
  • constant runny nose,
  • chest pain,
  • pain when you breathe,
  • fast heart rate,
  • rapid breathing,
  • shortness of breath (especially when lying down),
  • back pain,
  • swelling in your ankles or feet,
  • urinating less than usual or not at all,
  • confusion,
  • hallucinations,
  • feeling like you might pass out,
  • low blood sugar (headache, hunger, weakness, sweating, tremors, irritability, trouble concentrating),
  • muscle movements you cannot control,
  • loss of balance or coordination,
  • bloody or tarry stools,
  • coughing up blood or vomit that looks like coffee grounds, or
  • dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, or seizures).

Dosage for Cycloset

The recommended dose of Cycloset is 1.6 mg to 4.8 mg administered once daily within two hours after waking.

What Drugs, Substances, or Supplements Interact with Cycloset?

Cycloset may interact with antidepressants, sedatives, narcotics, medicines to treat psychiatric disorders, antibiotics, antifungal medications, anti-malaria drugs, asthma or allergy medications, cancer medicines, medicines used to prevent organ transplant rejection, cholesterol-lowering drugs, oral diabetes medications, heart or blood pressure medications, heart rhythm medications, HIV/AIDS medications, seizure medications, erectile dysfunction medicines, or stomach acid reducers. Tell your doctor all medications and supplements you use.

Cycloset During Pregnancy and Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant during treatment. Cycloset is not expected to harm a fetus. However, a pituitary tumor in the mother can expand during pregnancy. High blood pressure can also occur during pregnancy and this drug could be dangerous if taken by a pregnant woman with high blood pressure. Consult your doctor. This drug lowers the hormone needed to produce breast milk. Do not breastfeed while taking Cycloset.

Additional Information

Our Cycloset (bromocriptine mesylate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Diabetes is defined best as... See Answer
Cycloset Consumer Information

3 pharmacies near 20147 have coupons for Cycloset (Brand Names:Cycloset for 2.5MG)

Wegmans Food Markets Inc
Wegmans Food Markets Inc

Est. Regular Price


with free coupon

View Coupon

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • severe drowsiness; or
  • a light-headed feeling, like you might pass out.

You may have increased sexual urges, unusual urges to gamble, or other intense urges while taking this medicine. Talk with your doctor if this occurs.

Common side effects may include:

  • dizziness, feeling tired;
  • nausea, vomiting; or
  • headache.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Cycloset (Bromocriptine Mesylate Tablets)


Diabetes: What Raises and Lowers Your Blood Sugar Level? See Slideshow
Cycloset Professional Information


Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial, and may not reflect the rates actually observed in clinical practice.

In the pooled CYCLOSET phase 3 clinical trials (CYCLOSET N=2,298; placebo N=1,266), adverse events leading to discontinuation occurred in 539 (24%) CYCLOSET-treated patients and 118 (9%) placebo-treated patients. This between-group difference was driven mostly by gastrointestinal adverse events, particularly nausea.

The CYCLOSET safety trial was a 52-week, placebo-controlled study that included patients treated only with diet therapy or with other anti-diabetic medications. A total of 3,070 patients were randomized to CYCLOSET (titrated to 1.6 to 4.8 mg daily, as tolerated) or placebo. The study population had a mean baseline age of 60 years (range 27-80) and 33% were 65 years of age or older. Approximately 43% of the patients were female, 68% were Caucasian, 17% were Black, 13% were Hispanic, and 1% were Asian. The mean baseline body mass index was 32 kg/m2. The mean duration of diabetes at baseline was 8 years and the mean baseline HbA1c was 7.0% with a mean baseline fasting plasma glucose of 142 mg/dL. At baseline, 12% of patients were treated with diet only, 40% were treated with one oral anti-diabetic agent, 33% were treated with two oral anti-diabetic agents, and 16% were treated with insulin alone or insulin in combination with an oral anti-diabetic agent. At baseline, 76% of patients reported a history of hypercholesterolemia, 75% reported a history of hypertension, 11% reported a history of revascularization surgery, 10% reported a history of myocardial infarction, 10% reported a history of angina, and 5% reported a history of stroke. Forty-seven percent of the CYCLOSET-treated patients and 32% of the placebo-treated patients prematurely discontinued treatment. Adverse events leading to discontinuation of study drug occurred among 24% of the CYCLOSET-treated patients and 15% of the placebo-treated patients. This between-group difference was driven mostly by gastrointestinal adverse events, particularly nausea.

Table 1 summarizes the adverse events reported in ≥5% of patients treated with CYCLOSET in the phase 3 clinical trials regardless of investigator assessment of causality. The most commonly reported adverse events (nausea, fatigue, vomiting, headache, dizziness) lasted a median of 14 days and were more likely to occur during the initial titration of CYCLOSET. None of the reports of nausea or vomiting were described as serious. There were no differences in the pattern of common adverse events across race groups or age groups (<65 years old vs. >65 years old). In the 52-week CYCLOSET safety trial, 11.5% of CYCLOSET-treated women compared to 3.6% of placebo-treated women reported vomiting. In this same trial, 5.4% of CYCLOSET-treated men compared to 2.8% of placebo-treated men reported vomiting.

Table 1: Adverse Events Reported in Phase 3 Clinical Trials of CYCLOSET (≥5% of Patients and Numerically More Frequent in CYCLOSET-Treated Patients than in Placebo-Treated Patients, Regardless of Investigator Assessment of Causality†)

Monotherapy CYCLOSET 1.6 mg – 4.8 mg
N (%)
N (%)
N = 159 N = 80 N = 79
Nausea 26 (32.5) 6 (7.6)
Rhinitis 11 (13.8) 3 (3.8)
Headache 10 (12.5) 7 (8.9)
Asthenia 10 (12.5) 5 (6.3)
Dizziness 10 (12.5) 6 (7.6)
Constipation 9 (11.3) 3 (3.8)
Sinusitis 8 (10.0) 2 (2.5)
Diarrhea 7 (8.8) 4 (5.1)
Amblyopia 6 (7.5) 1 (1.3)
Dyspepsia 6 (7.5) 2 (2.5)
Vomiting 5 (6.3) 1 (1.3)
Infection 5 (6.3) 4 (5.1)
Anorexia 4 (5.0) 1 (1.3)
Adjunct to Sulfonylurea (2 pooled 24-week studies)
N = 494 N = 244 N = 250
Nausea 62 (25.4) 12 (4.8)
Asthenia 46 (18.9) 20 (8.0)
Headache 41 (16.8) 40 (16.0)
Flu syndrome 23 (9.4) 19 (7.6)
Constipation 24 (9.8) 11 (4.4)
Cold 20 (8.2) 20 (8.0)
Dizziness 29 (11.9) 14 (5.6)
Rhinitis 26 (10.7) 12 (4.8)
Sinusitis 18 (7.4) 16 (6.4)
Somnolence 16 (6.6) 5 (2.0)
Vomiting 13 (5.3) 8 (3.2)
Amblyopia 13 (5.3) 6 (2.4)
52-Week Safety Trial
N=3070 N = 2054 N = 1016
Nausea 661 (32.2) 77 (7.6)
Dizziness 303 (14.8) 93 (9.2)
Fatigue 285 (13.9) 68 (6.7)
Headache 235 (11.4) 84 (8.3)
Vomiting 167 (8.1) 32 (3.1)
Diarrhea 167 (8.1) 81 (8.0)
Constipation 119 (5.8) 52 (5.1)
†All randomized subjects receiving at least one dose of study drug
The Safety Trial enrolled patients treated with diet or no more than 2 anti-diabetic medications (metformin, insulin secretagogues such as a sulfonylurea, thiazolidinediones, alpha glucosidase inhibitors, and/or insulin)


In the monotherapy trial, hypoglycemia was reported in 2 CYCLOSET-treated patients (3.7%) and 1 placebo-treated patient (1.3%). In the add-on to sulfonylurea trials, the incidence of hypoglycemia was 8.6% among the CYCLOSET-treated patients and 5.2% among the placebo-treated patients. In the CYCLOSET safety trial, hypoglycemia was defined as any of the following: 1) symptoms suggestive of hypoglycemia that promptly resolved with appropriate intervention, 2) symptoms with a measured glucose <60 mg/dL or 3) measured glucose below 49 mg/dL regardless of symptoms. In the 52-week safety trial, the incidence of hypoglycemia was 6.9% among the CYCLOSET-treated patients and 5.3% among the placebo-treated patients. In the safety trial, severe hypoglycemia was defined as an inability to self-treat neurological symptoms consistent with hypoglycemia that occurred in the setting of a measured blood glucose <50 mg/dL (or evidence of prompt resolution of these symptoms with administration of oral carbohydrates, subcutaneous glucagon, or intravenous glucose if blood glucose was not measured). In this trial, severe hypoglycemia was reported among 0.5% of CYCLOSET-treated patients and 1% of placebo-treated patients.


In combined phase 2 and 3 clinical trials, syncope was reported in 1.4% of the 2,500 CYCLOSET-treated patients and 0.6% of the 1,454 placebo-treated patients. Among the 3,070 patients studied in the 52-week safety trial, 33 CYCLOSET-treated patients (1.6%) and 7 placebo-treated patients (0.7%) reported an adverse event of syncope. The cause of syncope is not known in all cases [see WARNINGS AND PRECAUTIONS]. In this trial, electrocardiograms were not available at the time of these events, but an assessment of routine electrocardiograms obtained during the course of the trial did not identify arrhythmias or QTc interval prolongation among the CYCLOSET-treated patients reporting syncope.

Central Nervous System

In the 52-week safety trial, somnolence and hypoesthesia were the only adverse events within the nervous system organ class that were reported at a rate of <5% and ≥1% and that occurred at a numerically greater frequency among CYCLOSET-treated patients (CYCLOSET 4.3% vs. Placebo 1.3% for somnolence; CYCLOSET 1.4% vs. Placebo 1.1% for hypoesthesia).

Serious Adverse Events And Cardiovascular Safety

The primary endpoint of the 52-week safety trial was the occurrence of all serious adverse events. A secondary endpoint was the occurrence of the composite of myocardial infarction, stroke, coronary revascularization, hospitalization for angina, and hospitalization for congestive heart failure.

All serious adverse events and cardiovascular endpoints were adjudicated by an independent event adjudication committee. Serious adverse events occurred in 176/2054 (8.5%) CYCLOSET-treated patients and 98/1016 (9.6%) placebo-treated patients. The hazard ratio comparing CYCLOSET to placebo for the time to first occurrence of a serious adverse event was 1.02 (upper bound of one-sided 96% confidence interval, 1.27). None of the serious adverse events grouped by System-Organ-Class occurred more than 0.3 percentage points higher with CYCLOSET than with placebo. The composite cardiovascular endpoint occurred in 31 (1.5%) CYCLOSET-treated patients and 30 (3.0%) placebo-treated patients. The hazard ratio comparing CYCLOSET to placebo for the timeto-first occurrence of the prespecified composite cardiovascular endpoint was 0.58 (two-sided 95% confidence interval, 0.35 . 0.96). Therefore, the incidence of this composite endpoint was not increased with CYCLOSET relative to placebo.

Postmarketing Experience

The active agent in CYCLOSET (bromocriptine mesylate) has been used in other formulations and often multiple times per day to treat hyperprolactinemia, acromegaly, and Parkinson’s disease. The following adverse reactions have been identified during post approval use of bromocriptine mesylate for these indications, generally at doses higher than those approved for the treatment of type 2 diabetes. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.


Hallucinations and mental confusion including delusions have been reported with bromocriptine. To date, there have been no reported cases of hallucinations or delusions among CYCLOSET-treated patients (n= 2500) in combined Phase 2 and 3 clinical trials of CYCLOSET.

Fibrotic-Related Complications

Fibrotic complications, including cases of retroperitoneal fibrosis, pulmonary fibrosis, pleural effusion, pleural thickening, pericarditis and pericardial effusions have been reported. These complications do not always resolve when bromocriptine is discontinued. Among several studies investigating a possible relation between bromocriptine exposure and cardiac valvulopathy, some events of cardiac valvulopathy have been reported, but no definitive association between bromocriptine mesylate use and clinically significant (moderate to severe) cardiac valvulopathy could be concluded.

To date, there have been no reported cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis or pericardial effusions among the CYCLOSET.treated patients (n=2500) in combined Phase 2 and 3 controlled clinical trials of CYCLOSET. There was one unconfirmed case (0.04% event rate) of an adverse event of pulmonary fibrosis classified as non-serious in a CYCLOSET-treated patient.

No cases of cardiac valvulopathy have been reported in any of the clinical studies to date with CYCLOSET.

Psychotic And Psychiatric Disorders

Psychotic disorders have been reported with bromocriptine. Additionally, pathological gambling has been reported with bromocriptine used to treat patients with Parkinson’s disease. To date, there have been no reported cases of psychoses or pathological gambling among the CYCLOSET-treated patients (N=2500) in combined Phase 2 and 3 controlled clinical trials of CYCLOSET.


The indication for use of bromocriptine for inhibition of postpartum lactation was withdrawn based on postmarketing reports of stroke. Causality of bromocriptine use and the occurrence of stroke in this patient population has not been proven. Based on the CYCLOSET clinical trials, there is no evidence of increased risk for stroke when CYCLOSET is used to treat type 2 diabetes.

Neuroleptic-Like Malignant Syndrome

A neuroleptic-like malignant syndrome (manifested by high fever and increase in creatinine phosphokinase) has been reported upon cessation of bromocriptine treatment in patients with advanced Parkinson’s disease or patients with secondary Parkinsonism. To date, there have been no reported cases of neuroleptic-like malignant syndrome in combined Phase 2 and 3 controlled clinical trials of CYCLOSET, including the Safety Trial (N=2500). In the CYCLOSET Safety Trial, there were no reports of neuroleptic-like malignant syndrome during the 30 days of follow-up after cessation of CYCLOSET (N = 2054).

Read the entire FDA prescribing information for Cycloset (Bromocriptine Mesylate Tablets)

© Cycloset Patient Information is supplied by Cerner Multum, Inc. and Cycloset Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors